Patents by Inventor Dwight-Steven Hill

Dwight-Steven Hill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7989678
    Abstract: The present invention relates “disarmed” strain variants of Agrobacterium strain K599 (NCPPB 2659), “disarmed” plasmid variants of the Ri-plasmid pRi2659, and derivatives thereof, and methods employing these strains and plasmids in plant transformation.
    Type: Grant
    Filed: August 31, 2005
    Date of Patent: August 2, 2011
    Assignee: BASF Plant Science GmbH
    Inventors: Luke Mankin, Dwight-Steven Hill, Paula Olhoft, Effie Toren, Jeffrey A. Brown, Liqun Xing, Huihua Fu, Lesley Ireland, Hongmei Jia, Hee-Sook Song, Allan Richard Wenck, Larry Nea
  • Publication number: 20070292953
    Abstract: The present invention relates “disarmed” strain variants of Agrobacterium strain K599 (NCPPB 2659), “disarmed” plasmid variants of the Ri-plasmid pRi2659, and derivatives thereof, and methods employing these strains and plasmids in plant transformation.
    Type: Application
    Filed: August 31, 2005
    Publication date: December 20, 2007
    Applicant: BASF Plant Science GmbH
    Inventors: Luke Mankin, Dwight-Steven Hill, Paula Olhoft, Effie Toren, Jeffrey Brown, Liqun Xing, Huihua Fu, Lesley Ireland, Hongmei Jia, Hee-Sook Song, Allan Wenck, Larry Nea
  • Publication number: 20030135880
    Abstract: This invention describes methods, transgenic plants and transgenic microorganisms for the biosynthesis of halogenated natural products, where the halogenation is substrate and regiospecific. In particular, this invention relates to the use of halogenated metabolites, produced by the method of the invention, for the protection of host organisms against pathogens, more particularly, to the protection of plants against phytopathogens. In this aspect, the invention provides transgenic plants with enhanced resistance to phytopathogens, and biocontrol organisms with enhanced biocontrol properties.
    Type: Application
    Filed: July 2, 2002
    Publication date: July 17, 2003
    Inventors: John Steffens, Chris Batie, Jon Marquiz Dietz, Jian Dong, Kim Puloma Kamdar, Dwight Steven Hill
  • Publication number: 20030068788
    Abstract: Disclosed is a family of P450 monooxygenases, each member of which regioselectively oxidizes avermectin to 4″-keto-avermectin. The P450 monooxgenases find use in methods and formulations for making emamectin from avermectin. Also disclosed are methods for purifying the P450 monooxygenases of the invention, binding agents that specifically bind to the P450 monooxygenases of the invention, and genetically engineered cells that express the P450 monooxygenases of the invention. Also disclosed are ferredoxins and ferredoxin reductases that are active with the P450 monooxygenases of the invention.
    Type: Application
    Filed: May 14, 2002
    Publication date: April 10, 2003
    Inventors: Thomas Gunther Buckel, Philip Eugene Hammer, Dwight Steven Hill, James Madison Ligon, Istvan Molnar Durham, Johannes Paul Pachlatko, Ross Eric Zirkle
  • Patent number: 6117670
    Abstract: The present invention is directed to the production of pyrrolnitrin in a host via recombinant expression of the polypeptides needed to biologically synthesize pyrrolnitrin. Genes isolated from P. fluorescens, P. pyrrocinia, B. cepacia, and M. fulvus that encode polypeptides necessary to produce pyrrolnitrin are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize pyrrolnitrin from any organism capable of producing pyrrolnitrin. The isolated genes may be transformed and expressed in a desired host organisms to produce pyrrolnitrin according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of pyrrolnitrin.
    Type: Grant
    Filed: February 24, 1998
    Date of Patent: September 12, 2000
    Assignee: Novartis Finance Corporation
    Inventors: James Madison Ligon, Dwight Steven Hill, Stephen Ting Lam, Philip Eugene Hammer, Karl-Heinz van Pee, Sabine Kirner, Thomas R. Young
  • Patent number: 5955348
    Abstract: Strains of Pseudomonas have been genetically engineered to have enhanced biocontrol properties. The strains of the invention are particularly effective against plant pathogenic fungi such as species of Rhizoctonia and Pythium, because the strains produce enhanced amounts of antifungal metabolites such as pyrrolnitrin that are active against these fungal pathogens. Both the genetically modified biocontrol strains and the antifungal metabolites can be used as active agents for biocontrol compositions.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: September 21, 1999
    Assignee: Novartis AG
    Inventors: James Madison Ligon, Nancy R. Torkewitz, Dwight Steven Hill, Thomas Deane Gaffney, Jill Michelle Stafford
  • Patent number: 5817502
    Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.
    Type: Grant
    Filed: October 9, 1996
    Date of Patent: October 6, 1998
    Assignee: Novartis Finance Corporation
    Inventors: James M. Ligon, Dwight Steven Hill, Stephen Ting Lam, Philip E. Hammer, Karl-Heinz van Pee, Sabine Kirner
  • Patent number: 5723759
    Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: March 3, 1998
    Assignee: Novartis Finance Corporation
    Inventors: James M. Ligon, Dwight Steven Hill, John Andrew Ryals, Stephen Ting Lam, Philip E. Hammer
  • Patent number: 5710031
    Abstract: Gene activating sequences which activate the expression of other bacterial genes, which are latent or expressed at low levels, are provided. The gene activating sequences confer the ability to produce several metabolites and may be transferred to bacterial strains. The transformed biocontrol agents are active to inhibit the growth of the fungal pathogens.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: January 20, 1998
    Assignee: Novartis Finance Corporation
    Inventors: Thomas D. Gaffney, Stephen T. Lam, James M. Ligon, Dwight Steven Hill, Jeffrey I. Stein
  • Patent number: 5698425
    Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: December 16, 1997
    Assignee: Novartis Finance Corporation
    Inventors: James M. Ligon, Thomas Schupp, James Joseph Beck, Dwight Steven Hill, John Andrew Ryals, Stephen Ting Lam, Philip E. Hammer, Scott Joseph Uknes
  • Patent number: 5679560
    Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: October 21, 1997
    Assignee: Novartis Finance Corporation
    Inventors: James M. Ligon, Dwight Steven Hill, Stephen Ting Lam, Philip E. Hammer
  • Patent number: 5670350
    Abstract: Gene activating sequences which activate the expression of other bacterial genes, which are latent or expressed at low levels, are provided. The gene activating sequences confer the ability to produce several metabolites and may be transferred to bacterial strains. The transformed biocontrol agents are active to inhibit the growth of the fungal pathogens.
    Type: Grant
    Filed: August 8, 1994
    Date of Patent: September 23, 1997
    Assignee: Novartis Finance Corporation
    Inventors: Thomas D. Gaffney, Stephen T. Lam, Dwight Steven Hill, Jeffrey I. Stein, James M. Ligon
  • Patent number: 5662898
    Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: September 2, 1997
    Assignee: Ciba-Geigy Corporation
    Inventors: James M. Ligon, Thomas Schupp, James Joseph Beck, Dwight Steven Hill, John Andrew Ryals, Thomas Deane Gaffney, Stephen Ting Lam, Philip E. Hammer, Scott Joseph Uknes
  • Patent number: 5643774
    Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: July 1, 1997
    Assignee: Ciba-Geigy Corporation
    Inventors: James M. Ligon, Thomas Schupp, James Joseph Beck, Dwight Steven Hill, John Andrew Ryals, Thomas Deane Gaffney, Stephen Ting Lam, Philip E. Hammer, Scott Joseph Uknes
  • Patent number: 5639949
    Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.
    Type: Grant
    Filed: June 8, 1994
    Date of Patent: June 17, 1997
    Assignee: Ciba-Geigy Corporation
    Inventors: James M. Ligon, Dwight Steven Hill, John Andrew Ryals, Stephen Ting Lam, Philip E. Hammer
  • Patent number: RE44750
    Abstract: The present invention relates “disarmed” strain variants of Agrobacterium strain K599 (NCPPB 2659), “disarmed” plasmid variants of the Ri-plasmid pRi2659, and derivatives thereof, and methods employing these strains and plasmids in plant transformation.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: February 4, 2014
    Assignee: BASF Plant Science GmbH
    Inventors: Luke Mankin, Dwight-Steven Hill, Paula Olhoft, Effie Toren, Jeffrey A. Brown, Liqun Xing, Huihua Fu, Lesley Ireland, Hongmei Jia, Hee-Sook Song, Allan R. Wenck, Larry Nea